Akums Drugs and Pharmaceuticals Analyst Review May 2026
- May 21, 2026
- Posted by: Kashish Aggarwal
- Category: News
This Akums Drugs and Pharmaceuticals analyst review for May 2026 covers the key data investors need for AKUMS at its current price of Rs 515.15. Akums Drugs and Pharmaceuticals (NSE: AKUMS) is one of India’s largest pharmaceutical CDMO companies with a market capitalisation of approximately Rs 5,500 crore. The analyst consensus target of Rs 680 implies meaningful upside, and this Akums Drugs and Pharmaceuticals analyst review examines technical levels, business performance, valuation, and key risks for AKUMS through FY27.
Click Here – Get Free Investment Predictions
Akums Drugs and Pharmaceuticals Company Snapshot May 2026
Akums’ CDMO business manufactures tablets, capsules, liquids, and injectables for 800 plus Indian pharma brands. The company also has a branded generics business in key therapeutic areas including anti-infectives and cardiovascular. The table below summarises the key data referenced in this Akums Drugs and Pharmaceuticals analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | AKUMS |
| Sector | Pharmaceuticals – CDMO and Branded |
| CMP (May 2026) | Rs 515.15 |
| 52 Week High | Rs 622.95 |
| 52 Week Low | Rs 409.30 |
| Market Cap | Rs 5,500 Crore |
| Trailing P/E | 30x |
| Analyst Consensus Target | Rs 680 |
| Bull Case Target | Rs 820 |
| Bear Case Target | Rs 440 |
Analyst Insight in This Akums Drugs and Pharmaceuticals Analyst Review
Senior Research Analyst Ankit Jaiswal flags Akums Drugs and Pharmaceuticals as a stock to watch in May 2026. At Rs 515.15, Ankit Jaiswal identifies key support in the Rs 417 to Rs 489 band and resistance near Rs 546. He suggests watching Akums Drugs and Pharmaceuticals for a potential move toward Rs 680, subject to Pharmaceuticals – CDMO and Branded sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Akums Drugs and Pharmaceuticals analyst review and does not constitute a trade recommendation.
Technical Analysis in This Akums Drugs and Pharmaceuticals Analyst Review
At Rs 515.15, AKUMS is trading within its 52-week band of Rs 409.30 to Rs 622.95. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 417 to Rs 489 band while resistance is seen in the Rs 546 to Rs 598 zone. A sustained move above Rs 546 could open the path toward the analyst consensus target of Rs 680 as identified in this Akums Drugs and Pharmaceuticals analyst review.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 417 to Rs 489 – investors tracking this Akums Drugs and Pharmaceuticals analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for AKUMS.
- Resistance Zone: Rs 546 to Rs 598 – a sustained close above Rs 546 would be a positive breakout signal worth flagging in this Akums Drugs and Pharmaceuticals analyst review.
- Medium-Term Target: The analyst consensus of Rs 680 represents the base-case upside scenario in this Akums Drugs and Pharmaceuticals analyst review.
Business Segment Analysis
Pharmaceutical CDMO (800 Plus Client Pharma Brands)
This is the primary revenue and margin driver for Akums Drugs and Pharmaceuticals, directly supporting the earnings trajectory toward the consensus target of Rs 680.
Branded Generic Formulations (Domestic Market)
This segment adds scale and diversification to Akums Drugs and Pharmaceuticals’s business model and is a meaningful EPS contributor through FY27 and FY28.
OTC Products and Consumer Healthcare
This represents the medium-term growth frontier for Akums Drugs and Pharmaceuticals and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Akums Drugs and Pharmaceuticals Analyst Review
At Rs 515.15, Akums Drugs and Pharmaceuticals trades at a trailing P/E of 30x. This Akums Drugs and Pharmaceuticals analyst review presents three scenarios: a bull case of Rs 820 on strong earnings delivery, a base case of Rs 680 at analyst consensus, and a bear case of Rs 440 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Akums Drugs and Pharmaceuticals analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 820 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 680 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 440 | Earnings miss or macro headwinds |
Trade Outlook for Akums Drugs and Pharmaceuticals
Based on the technical and fundamental analysis in this Akums Drugs and Pharmaceuticals analyst review, investors might watch AKUMS near the support zone of Rs 417 to Rs 489 for potential opportunities. A flag above Rs 546 could suggest improving momentum toward Rs 680. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Akums Drugs and Pharmaceuticals in FY27
A well-rounded Akums Drugs and Pharmaceuticals analyst review must assess downside risks. Key risks for Akums Drugs and Pharmaceuticals include a macro slowdown affecting Pharmaceuticals – CDMO and Branded sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in AKUMS.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Akums Drugs and Pharmaceuticals Analyst Review Verdict for 2026
This Akums Drugs and Pharmaceuticals analyst review concludes that at Rs 515.15, AKUMS offers a defined risk-reward with a consensus target of Rs 680. The 52-week range of Rs 409.30 to Rs 622.95 provides context on the current entry point. Use this Akums Drugs and Pharmaceuticals analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on AKUMS.
Frequently Asked Questions: Akums Drugs and Pharmaceuticals Analyst Review 2026
What is the analyst target for Akums Drugs and Pharmaceuticals in 2026?
The analyst consensus target is Rs 680, with a bull case of Rs 820 and a bear case of Rs 440. This Akums Drugs and Pharmaceuticals analyst review recommends monitoring Q1 FY27 earnings for confirmation.
Is Akums Drugs and Pharmaceuticals a good investment at Rs 515.15?
At Rs 515.15 with a P/E of 30x and a consensus target of Rs 680, this Akums Drugs and Pharmaceuticals analyst review is constructive for medium to long-term investors in the Pharmaceuticals – CDMO and Branded sector. Always consult a SEBI-registered advisor before investing.
What is Akums Drugs and Pharmaceuticals’s 52-week high and low?
The 52-week high is Rs 622.95 and the 52-week low is Rs 409.30. At Rs 515.15, AKUMS is positioned within this range as noted in this Akums Drugs and Pharmaceuticals analyst review.
What are the key risks for Akums Drugs and Pharmaceuticals?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – CDMO and Branded sector as assessed in this Akums Drugs and Pharmaceuticals analyst review.
Where can I track live data for Akums Drugs and Pharmaceuticals?
Track Akums Drugs and Pharmaceuticals’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Akums Drugs and Pharmaceuticals analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
